

ALASKA MEDICAID  
Prior Authorization Criteria

**Xcopri®  
(cenobamate)**

**FDA INDICATIONS AND USAGE**<sup>1</sup>

Xcopri® is a voltage-gated sodium channel inhibitor and a positive allosteric modulator of the  $\gamma$ -aminobutyric acid (GABA<sub>A</sub>) ion channel. It is indicated for the treatment of partial-onset seizures in adult patients.

**APPROVAL CRITERIA**<sup>1,2</sup>

1. Patient is 18 years of age or older **AND;**
2. The medication is being prescribed by or in consultation with a neurologist or physician that specializes in seizure disorders **AND;**
3. The patient has the diagnosis of partial-onset seizures **AND;**
4. The patient has tried and failed or has a contraindication to two anticonvulsants indicated for partial seizures.

**DENIAL CRITERIA**<sup>1,2</sup>

1. Failure to meet approval criteria **OR;**
2. The patient has Familial Short QT syndrome **OR;**
3. Dosages exceeding 400mg per day.

**CAUTIONS**<sup>1</sup>

- Dosage adjustments may be needed when concomitantly being prescribed with other medications.
- Monitor patients for suicidal behavior and ideation.
- Monitor for somnolence and fatigue and advise patients not to drive or operate machinery until they have gained sufficient experience on XCOPRI. Concomitant use with other CNS depressants or alcohol may have additive effects.
- Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI.

**DURATION OF APPROVAL**

- Initial Approval: up to 3 months
- Reauthorization Approval: up to 12 months

ALASKA MEDICAID  
Prior Authorization Criteria

**QUANTITY LIMIT**

- 30 days (not to exceed maximum dose 400mg per day)

**REFERENCES / FOOTNOTES:**

1. Xcopri [prescribing information]. Paramus, NJ: SK Life Sciences, Inc.; August 2020.
2. Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicenter, double-blind, randomized, placebo-controlled, dose-response trial. *Lancet Neurology* 2019; published online November 13, 2019; [https://doi.org/10.1016/S1474-4422\(19\)30399-0](https://doi.org/10.1016/S1474-4422(19)30399-0).